The anti-IL5 antibody mepolizumab was approved in 2015 and since then has become an established therapy for patients with severe uncontrolled eosinophilic asthma Difficult-to-treat and severe asthma in adolescent and adult patients. The gene discussed is IL5; the disease is asthma.